UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation

Science (American Association for the Advancement of Science), 2009-08, Vol.325 (5944), p.1134-1138

2009

Volltextzugriff (PDF)

TAK1 Is Essential for Osteoclast Differentiation and Is an Important Modulator of Cell Death by Apoptosis and Necroptosis

Molecular and Cellular Biology, 2013-02, Vol.33 (3), p.582-595

2013

Volltextzugriff (PDF)

E2 interaction and dimerization in the crystal structure of TRAF6

Nature structural & molecular biology, 2009-06, Vol.16 (6), p.658-666

2009

Volltextzugriff (PDF)

Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2

Biochemistry (Easton), 2009-11, Vol.48 (44), p.10558-10567

2009

Volltextzugriff (PDF)

The RING Domain and First Zinc Finger of TRAF6 Coordinate Signaling by Interleukin-1, Lipopolysaccharide, and RANKL

The Journal of biological chemistry, 2008-09, Vol.283 (36), p.24871-24880

2008

Volltextzugriff (PDF)

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

JNCI : Journal of the National Cancer Institute, 2008-07, Vol.100 (13), p.926-939

2008

Volltextzugriff (PDF)

The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway

BMC biology, 2004-11, Vol.2 (1), p.24-24, Article 24

2004

Volltextzugriff (PDF)

Critical Role of Monoubiquitination of Histone H2AX Protein in Histone H2AX Phosphorylation and DNA Damage Response

The Journal of biological chemistry, 2011-09, Vol.286 (35), p.30806-30815

2011

Volltextzugriff (PDF)

TAK1-dependent Signaling Requires Functional Interaction with TAB2/TAB3

The Journal of biological chemistry, 2007-02, Vol.282 (6), p.3918-3928

2007

Volltextzugriff (PDF)

P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR‐LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER‐104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS

HemaSphere, 2023-08, Vol.7 (S3), p.e41693dd-n/a

2023

Volltextzugriff (PDF)

FRS2α Attenuates FGF Receptor Signaling by Grb2-Mediated Recruitment of the Ubiquitin Ligase Cbl

Proceedings of the National Academy of Sciences - PNAS, 2002-05, Vol.99 (10), p.6684-6689

2002

Volltextzugriff (PDF)

Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice

PloS one, 2012-12, Vol.7 (12), p.e51228

2012

Volltextzugriff (PDF)

The Docking Protein Gab1 Is an Essential Component of an Indirect Mechanism for Fibroblast Growth Factor Stimulation of the Phosphatidylinositol 3-Kinase/Akt Antiapoptotic Pathway

Molecular and Cellular Biology, 2004-07, Vol.24 (13), p.5657-5666

2004

Volltextzugriff (PDF)

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

Clinical cancer research, 2015-08, Vol.21 (16), p.3705-3715

2015

Volltextzugriff (PDF)

Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses

Clinical cancer research, 2016-09, Vol.22 (18), p.4712-4726

2016

Volltextzugriff (PDF)

Site-specific Lys-63-linked Tumor Necrosis Factor Receptor-associated Factor 6 Auto-ubiquitination Is a Critical Determinant of IκB Kinase Activation

The Journal of biological chemistry, 2007-02, Vol.282 (6), p.4102-4112

2007

Volltextzugriff (PDF)

Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60

Journal of interferon & cytokine research, 2002-02, Vol.22 (2), p.269-279

2002

Volltextzugriff (PDF)

Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7017-7017

2023

Volltextzugriff (PDF)

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Blood, 2022-11, Vol.140 (Supplement 1), p.3943-3944

2022

Volltextzugriff (PDF)

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy

Leukemia, 2018-04, Vol.32 (4), p.920-930

2018

Volltextzugriff (PDF)

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood, 2023-11, Vol.142 (Supplement 1), p.624-624

2023

Volltextzugriff (PDF)

MPN-548 Phase I/II Study of the Activin Receptor-Like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S401-S402

2023

Volltextzugriff (PDF)

POSTER: MPN-548 Phase I/II Study of the Activin Receptor-like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S195-S195

2023

Volltextzugriff (PDF)

TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation

Biochemical and biophysical research communications, 2007-08, Vol.359 (4), p.1044-1049

2007

Volltextzugriff (PDF)

Molecular Basis for the Unique Deubiquitinating Activity of the NF-κB Inhibitor A20

Journal of molecular biology, 2008-02, Vol.376 (2), p.526-540

2008

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(63)
Bücher
(1)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation

TAK1 Is Essential for Osteoclast Differentiation and Is an Important Modulator of Cell Death by Apoptosis and Necroptosis

E2 interaction and dimerization in the crystal structure of TRAF6

Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2

The RING Domain and First Zinc Finger of TRAF6 Coordinate Signaling by Interleukin-1, Lipopolysaccharide, and RANKL

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway

Critical Role of Monoubiquitination of Histone H2AX Protein in Histone H2AX Phosphorylation and DNA Damage Response

TAK1-dependent Signaling Requires Functional Interaction with TAB2/TAB3

P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR‐LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER‐104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS

FRS2α Attenuates FGF Receptor Signaling by Grb2-Mediated Recruitment of the Ubiquitin Ligase Cbl

Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice

The Docking Protein Gab1 Is an Essential Component of an Indirect Mechanism for Fibroblast Growth Factor Stimulation of the Phosphatidylinositol 3-Kinase/Akt Antiapoptotic Pathway

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses

Site-specific Lys-63-linked Tumor Necrosis Factor Receptor-associated Factor 6 Auto-ubiquitination Is a Critical Determinant of IκB Kinase Activation

Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60

Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF)

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

MPN-548 Phase I/II Study of the Activin Receptor-Like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis

POSTER: MPN-548 Phase I/II Study of the Activin Receptor-like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis

TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation

Molecular Basis for the Unique Deubiquitinating Activity of the NF-κB Inhibitor A20

Suchergebnisse filtern